Brief: U.S. FDA Grants Orphan Drug Designation To Jr-441 For The Treatment Of Mucopolysaccharidosis Type Iiia (Mps Iiia)

JCR Pharmaceuticals

15/12/2023 12:38

Dec 15 (Reuters) - JCR Pharmaceuticals Co Ltd  4552.T :
    * U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO JR-441 FOR THE
TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IIIA (MPS IIIA)
    * JCR PHARMACEUTICALS CO LTD - CURRENTLY CONDUCTING GLOBAL
PHASE
I/II CLINICAL TRIAL FOR JR-441, WITH FIRST PATIENT WITH MPS IIIA
DOSED IN OCTOBER 2023 
    * JCR PHARMACEUTICALS CO: THERE IS MINOR IMPACT ON OUR
CONSOLIDATED BUSINESS RESULTS FOR THIS FISCAL YEAR ENDING ON
MARCH 31, 2024 RELATED TO JR-441

Source text for Eikon:  ID: 
Further company coverage:  4552.T 

 ((Reuters.Briefs@thomsonreuters.com;))